World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
46
Citations
16604
World Ranking
4566
National Ranking
2057

Maria R. Parkhurst publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Maria R. Parkhurst sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 134 publications — 11th percentile

11% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Maria R. Parkhurst D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Maria R. Parkhurst sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 46 D-Index — 8th percentile

8% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Maria R. Parkhurst is affiliated with the National Institutes of Health in the United States and has contributed extensively to the fields of Medicine and Immunology and Microbiology. Their research primarily focuses on Oncology and Immunology, with additional work in Genetics, Molecular Biology, and Radiology, Nuclear Medicine and Imaging.

The main topics covered in Parkhurst's research include:

  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Cancer Immunotherapy and Biomarkers
  • Immune Cell Function and Interaction
  • T-cell and B-cell Immunology
  • Virus-based gene therapy research
  • Vaccines and immunoinformatics approaches

Several frequent co-authors have collaborated with Parkhurst on multiple scientific publications, including:

  • Steven A. Rosenberg
  • Frank J. Lowery
  • Paul F. Robbins
  • Jared J. Gartner
  • Sri Krishna

Parkhurst's recent influential papers include:

  • Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer, 2020, Science
  • Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers, 2022, Science
  • mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer, 2020, Journal of Clinical Investigation
  • A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers, 2022, Cancer Cell
  • Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors, 2022, Cancer Immunology Research

Parkhurst's work has appeared prominently in several publication venues, notably:

  • Regular and Young Investigator Award Abstracts
  • Cancer Cell
  • Nature Medicine
  • Cancer Research
  • Science

Best Publications

  • Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

    Eric Tran;Simon Turcotte;Alena Gros;Paul F. Robbins

  • Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

    Steven A. Rosenberg;James C. Yang;Douglas J. Schwartzentruber;Patrick Hwu

  • T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

    Maria R. Parkhurst;James C. Yang;Russell C. Langan;Mark E. Dudley

  • Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients

    Alena Gros;Maria R Parkhurst;Eric Tran;Anna Pasetto

  • Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.

    Maria R. Parkhurst;Michael L. Salgaller;Scott Southwood;Paul F. Robbins

  • GP100/PMEL 17 IS A MURINE TUMOR REJECTION ANTIGEN : INDUCTION OF SELF -REACTIVE, TUMORICIDAL T CELLS USING HIGH-AFFINITY, ALTERED PEPTIDE LIGAND

    Willem W. Overwijk;Allan Tsung;Kari R. Irvine;Maria R. Parkhurst

  • Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression

    Maria R. Parkhurst;John P. Riley;Mark E. Dudley;Steven A. Rosenberg

  • Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers

    Unknown

  • Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer

    Sri Krishna;Frank J. Lowery;Amy R. Copeland;Erol Bahadiroglu

  • Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes

    Cyrille J. Cohen;Cyrille J. Cohen;Jared J. Gartner;Miryam Horovitz-Fried;Katerina Shamalov

  • Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen.

    Rong Fu Wang;Maria R. Parkhurst;Yutaka Kawakami;Paul F. Robbins

  • Melanoma-specific CD4 + T Cells Recognize Nonmutated HLA-DR-restricted Tyrosinase Epitopes

    Suzanne L. Topalian;Monica I. Gonzales;Maria Parkhurst;Yong F. Li

  • mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer

    Gal Cafri;Jared J Gartner;Tal Zaks;Kristen Hopson

  • Identification of a Shared HLA-A*0201-restricted T-Cell Epitope from the Melanoma Antigen Tyrosinase-related Protein 2 (TRP2)

    Maria R. Parkhurst;Ellen B. Fitzgerald;Scott Southwood;Alessandro Sette

  • Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers

    Maria R. Parkhurst;Paul F Robbins;Eric Tran;Todd D. Prickett

  • Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers

    Parisa Malekzadeh;Anna Pasetto;Paul F. Robbins;Maria R. Parkhurst

  • A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers.

    Unknown

  • Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.

    Rami Yossef;Eric Tran;Drew C. Deniger;Alena Gros

  • A TCR Targeting the HLA-A*0201–Restricted Epitope of MAGE-A3 Recognizes Multiple Epitopes of the MAGE-A Antigen Superfamily in Several Types of Cancer

    Nachimuthu Chinnasamy;Jennifer A. Wargo;Zhiya Yu;Mahadev Rao

  • Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor

    Anna Pasetto;Alena Gros;Paul F. Robbins;Drew C. Deniger

  • Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression

    Maria R. Parkhurst;Alena Gros;Anna Pasetto;Todd D. Prickett

  • Characterization of Genetically Modified T-Cell Receptors that Recognize the CEA:691-699 Peptide in the Context of HLA-A2.1 on Human Colorectal Cancer Cells

    Maria R. Parkhurst;Jayne S Joo;John P. Riley;Zhiya Yu

Frequent Co-Authors

Steven A. Rosenberg
Steven A. Rosenberg National Institutes of Health
Paul F. Robbins
Paul F. Robbins National Cancer Institute
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
Nicholas P. Restifo
Nicholas P. Restifo National Institutes of Health
Paul D. Robbins
Paul D. Robbins University of Minnesota
Zhiya Yu
Zhiya Yu National Institutes of Health
John R. Wunderlich
John R. Wunderlich National Institutes of Health
Yutaka Kawakami
Yutaka Kawakami International University Of Health And Welfare Atami Hospital
Richard A. Morgan
Richard A. Morgan University of California, Los Angeles
Mark E. Dudley
Mark E. Dudley Novartis (Switzerland)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in immunology, pursuing related healthcare degrees can open diverse career opportunities. Many professionals choose to advance their clinical skills by exploring specialized nursing roles. For example, enrolling in acute care nurse practitioner programs helps nurses transition from general practice to acute care settings, expanding their expertise in managing complex patient needs.

Accelerated pathways are particularly valuable for those who want to fast-track their education. Accelerated NP programs online offer flexible learning options that accommodate busy schedules, allowing students to earn nurse practitioner credentials more quickly and efficiently.

Individuals new to nursing can also explore foundational programs. For instance, online RN programs for non nurses in Florida provide accessible entry points into the nursing profession, ideal for those shifting careers into healthcare and immunology-related fields.

Salary potential is an important consideration when selecting a degree. Understanding how much does a DNP make can help guide career decisions by highlighting earning prospects across different states and specialties.

Best Scientists Citing Maria R. Parkhurst

Trending Scientists

Recently Published Articles